Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Still a Buy?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up before the market opened on Monday . The stock had previously closed at $19.11, but opened at $21.36. Ascentage Pharma Group International shares last traded at $21.0670, with a volume of 5,707 shares.

Analyst Ratings Changes

AAPG has been the topic of a number of research analyst reports. Lucid Cap Mkts upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Rodman & Renshaw started coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price objective on the stock. BTIG Research assumed coverage on shares of Ascentage Pharma Group International in a research report on Thursday, March 12th. They issued a “buy” rating and a $48.00 price objective on the stock. Oppenheimer assumed coverage on shares of Ascentage Pharma Group International in a research note on Thursday, December 4th. They set an “outperform” rating and a $45.00 target price for the company. Finally, Truist Financial set a $51.00 target price on shares of Ascentage Pharma Group International in a report on Monday, November 24th. Two equities research analysts have rated the stock with a Strong Buy rating and five have issued a Buy rating to the company. According to MarketBeat, Ascentage Pharma Group International presently has a consensus rating of “Buy” and an average target price of $48.00.

Ascentage Pharma Group International Stock Performance

The stock has a 50 day moving average price of $24.57 and a two-hundred day moving average price of $30.35. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Tema Etfs LLC acquired a new stake in shares of Ascentage Pharma Group International during the second quarter worth $610,000. XY Capital Ltd grew its stake in shares of Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares in the last quarter. UBS Group AG increased its position in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares during the period. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International during the second quarter worth about $391,000. Finally, Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International in the 3rd quarter worth about $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.